A study of the interplay effect for VMAT SBRT using a four-axes motion phantom.

interplay motion radiotherapy respiratory stereotactic body radiation therapy (SBRT) volumetric modulated arc therapy (VMAT)

Journal

Journal of applied clinical medical physics
ISSN: 1526-9914
Titre abrégé: J Appl Clin Med Phys
Pays: United States
ID NLM: 101089176

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 23 01 2020
revised: 08 05 2020
accepted: 11 05 2020
pubmed: 24 6 2020
medline: 22 6 2021
entrez: 24 6 2020
Statut: ppublish

Résumé

To assess the accuracy of volumetric modulated arc therapy (VMAT) stereotactic body radiation therapy (SBRT) when treating moving targets (such as lung or liver lesions), focusing on the impact of the interplay effect in the event of complex breathing motion and when a gating window is used. A dedicated programmable motion platform was implemented. This platform can carry large quality assurance (QA) phantoms and achieve complex three-dimensional (3D) motion. Volumetric modulated arc therapy SBRT plans were delivered with TrueBeam linac to this moving setup and the measured dose was compared to the computed one. Several parameters were assessed such as breathing period, dose rate, dose prescription, shape of the breathing pattern, the use of a planning target volume (PTV) margin, and the use of a gating window. Loss of dose coverage (D95%) was acceptable in most situations. The doses received by 95% of the CTV, D95% ( In our clinical context, treating lung and liver lesions using VMAT SBRT is reasonable. The interplay effect was moderated and acceptable in all simulated situations.

Identifiants

pubmed: 32573908
doi: 10.1002/acm2.12947
pmc: PMC7484847
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

208-215

Informations de copyright

© 2020 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine.

Références

Med Phys. 2006 Oct;33(10):3874-900
pubmed: 17089851
Radiother Oncol. 2019 May;134:44-49
pubmed: 31005223
Phys Med Biol. 2019 Jan 08;64(2):025006
pubmed: 30618412
Phys Med Biol. 2018 Apr 19;63(8):085012
pubmed: 29671410
Med Phys. 1999 May;26(5):715-20
pubmed: 10360531
J Appl Clin Med Phys. 2006 Nov 28;7(4):50-65
pubmed: 17533356
Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):1081-92
pubmed: 11704333
Med Phys. 2016 Dec;43(12):6364
pubmed: 27908156
Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):743-8
pubmed: 23773394
Acta Oncol. 2011 May;50(4):528-38
pubmed: 21338272
J Ultrasound Med. 1984 Jul;3(7):317-20
pubmed: 6748150
Semin Radiat Oncol. 2004 Jan;14(1):41-51
pubmed: 14752732
ANZ J Surg. 2019 Sep;89(9):1138-1143
pubmed: 30983104
Med Phys. 2003 Jun;30(6):1103-9
pubmed: 12852534
Adv Radiat Oncol. 2019 Jan 24;4(2):422-428
pubmed: 31011688
Phys Med Biol. 2003 Jun 21;48(12):1773-84
pubmed: 12870582
J Appl Clin Med Phys. 2018 Sep;19(5):517-524
pubmed: 30009564
Br J Cancer. 2018 Aug;119(4):389-407
pubmed: 30061587
J Appl Clin Med Phys. 2013 Nov 04;14(6):4370
pubmed: 24257279
Int J Radiat Oncol Biol Phys. 1990 Mar;18(3):671-7
pubmed: 2318701
Acta Radiol Diagn (Stockh). 1984;25(2):129-31
pubmed: 6731017
HPB Surg. 2010;2010:
pubmed: 20689733
Eur J Cancer. 2009 Nov;45(17):2947-59
pubmed: 19773153
Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1298-306
pubmed: 15519803
Phys Med Biol. 2019 May 08;64(10):105002
pubmed: 30995614
Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):265-78
pubmed: 11316572
Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):478-92
pubmed: 26867877

Auteurs

Jermey Leste (J)

INSERM, Toulouse, France.

Imene Medjahed (I)

IUCT-Oncopole, Toulouse, France.

François-Xavier Arnaud (FX)

IUCT-Oncopole, Toulouse, France.

Regis Ferrand (R)

INSERM, Toulouse, France.
IUCT-Oncopole, Toulouse, France.

Xavier Franceries (X)

IUCT-Oncopole, Toulouse, France.

Manuel Bardies (M)

INSERM, Toulouse, France.

Luc Simon (L)

INSERM, Toulouse, France.
IUCT-Oncopole, Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH